- Insiders intend to acquire up to approximately 10% of BriaCell’s basic common shares, or 1.59 million shares
- Corporate buyback program will continue; 501,703 shares and 143,236 warrants repurchased since program commencement
$5.1 million proceeds received via warrant exercises sinceNovember 1, 2021
The Insiders may purchase approximately 1.59 million common shares and/or publicly-listed common share purchase warrants (the “Securities”) on the open market, representing approximately 10% of basic common shares outstanding within the six month period commencing
Insiders’ proposed purchases may be conducted through open-market transactions at prevailing market prices and/or through other legally permissible means, subject to the market conditions and in compliance with applicable securities laws, rules and regulations. The timing and dollar amount of Insiders’ purchases may vary individually. BriaCell’s Board of Directors will be reviewing the program periodically and may suspend or discontinue the program.
BriaCell Corporate Buyback Program Will Continue
Purchases of Securities by Insiders may coincide with BriaCell’s ongoing normal course issuer bid (the “Buyback”), being executed through the Company’s independent advisor and dealer manager
Pursuant to the Buyback program announced
BriaCell’s cash balance as of
Separately, since
About
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the
Neither
Contact Information
Company Contact:
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Source:
2021 GlobeNewswire, Inc., source